<DOC>
	<DOCNO>NCT02703311</DOCNO>
	<brief_summary>The Cardioband Transcatheter System ( Cardioband ) indicate treatment secondary ( functional ) mitral regurgitation ( FMR ) . The Cardioband transcatheter system , deploy beat heart transseptal approach . The Cardioband deploy along posterior annulus mitral valve ( MV ) adjust trans-esophageal guidance beat heart . A CE mark study 30 subject complete documented reduction severity mitral regurgitation ( MR ) improvement 6- minute walk test subject moderate severe MR. Study objectives test efficacy Cardioband improve MR heart failure symptoms patient symptomatic ( New York Heart Association ( NYHA ) Class III-IVa ) , severe MR post-marketing setting , And evaluate safety Cardioband system post-marketing setting .</brief_summary>
	<brief_title>REPAIR - transcatheteR rEPair mitrAl Insufficiency With caRdioband System</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Severe ( 3+ 4+ ) secondary Mitral Regurgitation 3 . Symptomatic heart failure ( NYHA Class IIIIVa ) despite guideline direct medical therapy include CRT indicate 4 . The Local Site Heart Team concur surgery offer treatment option medical therapy intend therapy . 5 . Transfemoral access transseptal deployment Cardioband determine feasible 6 . Subject willing able provide inform consent follow protocol 1 . EF &lt; 20 % 2 . LVEDD ≥ 70 mm 3 . Heavily calcified annulus leaflet 4 . Significant CAD require revascularization 5 . Active bacterial endocarditis 6 . Any percutaneous coronary , carotid , endovascular intervention carotid surgery within 30 day coronary endovascular surgery within 3 month 7 . Renal insufficiency require dialysis 8 . Life expectancy less twelve month 9 . Subject participate concomitant research study investigational product reach primary endpoint 10 . Pulmonary hypertension ≥ 70mmHg rest 11 . Mitral valve anatomy may preclude proper device treatment 12 . Rightsided congestive heart failure echocardiographic evidence severe right ventricular dysfunction and/or severe tricuspid regurgitation 13 . Severe liver disease 14 . Patient pregnant lactate 15 . Hypersensitivity Nickel Chromium 16 . Clinically significant bleeding diathesis coagulopathy 17 . History mitral valve repair 18 . TIA CVA within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Valtech Cardio</keyword>
	<keyword>Cardioband</keyword>
	<keyword>Mitral Valve</keyword>
</DOC>